Epratuzumab, AREA[OverallStatus], Open or Pending: 1 Clinical Trial

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Condition(s):Blasts 5 Percent or More of Bone Marrow Nucleated Cells; CD22 Positive; Philadelphia Chromosome Positive; Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic LeukemiaLast Updated:December 8, 2022Recruiting

Trial Bulletin .com

Clinical Trials by Category

Clinical Trials Alphabetically

About

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.